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T he traditional treatment strategy for patients withaneurysm of the descending thoracic aorta is surgi-
cal intervention with graft interposition.1 Since the first
reports of successful operative repair more than 45
years ago,2,3 substantial clinical advances in the surgical
management of these patients has led to a decline in the
operative mortality risk to the range of 5% to 20%.4-6
Nevertheless, open surgical graft replacement of aneurysms
is still associated with substantial morbidity and mortality
for a patient population that is frequently elderly and debil-
itated with other serious medical problems. In addition, the
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operative mortality rate is nearly 50% in patients requiring
emergency operative treatment.4-7
The endoluminal placement of stent-grafts is a new,
less invasive alternative technique for repair of aortic
aneurysms that was initially introduced by Dotter8 in
1969. Subsequently, other investigators experimented
with stent-grafts in animal models of abdominal aortic
aneurysms.9-12 The first clinical use of stent-grafts for
repair of abdominal aortic aneurysms was reported by
Parodi, Palmaz, and Barone13 in 1991. Since then,
endovascular stent-graft placement for the treatment of
aneurysms in the abdominal aorta, descending thoracic
aorta, subclavian or iliac arteries, as well as arteriove-
nous fistulas, has been clinically investigated in a num-
ber of centers.14-21 The initial results of these feasibili-
ty studies suggest that this approach is an attractive
alternative to open surgical repair that may potentially
reduce the operative risk, hospital stay, and procedural
cost in selected patients.
In July 1992, we initiated this investigation into the
feasibility of stent-graft treatment of patients with
aneurysms of the descending thoracic aorta. This report
summarizes our 5-year experience with an admittedly
primitive “first generation,” custom-made, self-expand-
ing prosthesis in 103 patients, expands on previous
reports16,21 conveying early results, and documents the
many complications that arose during a mean follow-
up period of 1.8 years (maximum 5.3 years). This
report also summarizes clinical and anatomic factors
that predicted adverse outcomes and thereby illumi-
nates where the future challenges lie and focuses the
direction of future research in this field.
Methods
From July 1992 through October 1997, 103 patients in
whose treatment a cardiovascular surgeon from the
Department of Cardiothoracic Surgery was involved under-
went transluminal endovascular stent-graft placement for
repair of thoracic aortic aneurysms at Stanford University
Medical Center. The procedures were performed with the use
of an investigational protocol approved by the Institutional
Review Board of Stanford University Medical Center.
Informed consent was obtained from every patient before the
procedure. All patients underwent chest radiography, spiral
computed tomographic (CT) scanning with 3-dimensional
vascular reconstruction, and arteriography before stent place-
ment and at intervals afterward, as defined by protocol. Spiral
CT and arteriography using a graduated catheter assessed the
lengths and diameters of the aneurysm and its proximal and
distal necks, or so-called “landing zones.” In addition, these
studies identified the relationship between the aneurysm and
significant aortic branches, especially the left subclavian
artery and the celiac axis. Abdominal and pelvic arteriogra-
phy was used to determine the diameter and tortuosity of the
abdominal aorta and the iliac and femoral arteries through
which the stent-graft is delivered. Patient evaluation and
selection was a true collaborative judgment effort involving
both cardiovascular surgeons and interventional radiologists.
Ideally, the proximal and distal aneurysm necks (or “land-
ing zones”) should be longer than 20 mm and cylindrical. If
the distance between the origin of the left subclavian artery
and the proximal aspect of the aneurysm was insufficient, the
left subclavian artery was moved to create a longer proximal
neck. The procedures were performed in the operating theater
or angiographic suite with the patient under general anesthe-
sia. In the operating room, the procedure was guided by
means of a portable digital C-arm image intensifier system
and transesophageal echocardiography. In the angiographic
suite, a stationary angiography unit capable of rapid-
sequence computerized imaging and road map guidance was
used. The implantations were performed by coordinated
teams of interventional radiologists and cardiovascular sur-
geons working in concert.
The endovascular stent-graft was custom-fabricated on the
basis of each patient’s pathologic anatomy and composed of
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Fig 1. Histogram illustrating the number of endovascular stent-grafts carried out per year to repair descending tho-
racic aortic aneurysms. Also shown, for perspective, is the number of conventional open surgical graft replacement
procedures each year for patients with descending thoracic aortic aneurysms on our service. S-G, Stent-graft.
individual self-expanding Z-shaped stainless steel (2.5 cm
long) stent bodies (Cook, Inc, Bloomington, Ind) intercon-
nected by 2-0 polypropylene suture that ran circumferential-
ly through the eyelets at the apex of each Z-bend. This cylin-
dric metallic endoskeleton was covered with uncrimped
woven polyester graft material (Cooley Veri-Soft, Meadox
Medicals/Boston Scientific Corporation, Oakland, NJ). The
graft was attached to the stent at its ends by a series of 5-0
interrupted polypropylene sutures. The diameter of the stent-
graft was oversized by 10% to 15% compared with the aortic
neck diameter measured on CT to provide residual radial
force and an effective friction seal against the aortic wall after
stent-graft deployment. The device was sterilized with ethyl-
ene oxide.
Patients were positioned in various degrees of the right lat-
eral decubitus position on a radiolucent table and draped ster-
ilely for emergency left thoracotomy in case serious compli-
cations ensued. The groins, pelvis, abdomen, and flanks were
also prepared and draped to gain suitable femoral, iliac, or
retroperitoneal abdominal aortic access, as determined indi-
vidually for each patient. A double-lumen endobronchial
tube, transesophageal echocardiography probe, and pul-
monary artery catheter were introduced in most cases, and a
cell salvage system and cardiopulmonary bypass (CPB)
standby were available. With the patient under general anes-
thesia, the exposure and aortic access were performed by the
surgeon, and the radiologist deployed the stent-graft after
coordinated discussions took place concerning optimal posi-
tioning of the device. The details of the technique of inserting
the stent-graft and postprocedural patient management have
been described previously.16,21
These selected 103 patients who received endovascular
stent-grafts to treat a descending thoracic aortic aneurysm
had a heterogeneous mix of aneurysm causes and risk factors.
Table I lists the baseline clinical characteristics of the
patients, and Fig 1 depicts the use of endovascular stent-
grafts over time. Sixty-two of the 103 patients (60%) under-
going stent-grafting were judged by one of the surgeons not
to be reasonable operative candidates for conventional
“open” surgical repair because of a variety of pulmonary, car-
diac, or other medical problems. During this same time inter-
val, 186 other patients underwent open surgical graft replace-
ment of descending thoracic aneurysms on our service; thus
36% ± 3% of patients treated in this time frame received an
endovascular stent-graft. Twelve patients (12%) had stent-
grafts placed for management of acute aortic rupture. A pre-
viously repaired or coexisting abdominal aortic aneurysm
was identified in 47 (46%). Twenty-one additional patients
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Table I. Preoperative clinical characteristics of 103
patients with descending thoracic aortic aneurysms who
were treated with transluminal endovascular stent-grafts
Characteristic Value Percent
Sex (No. of patients)
Male 73 71
Female 30 29
Age (y)
Mean 76 ± 12
Range 34-89
Operative status (No. of patients)
Emergency 16 16
Nonemergency 87 84
Other medical problems (No. of patients)
Angina
Stable 17 17
Unstable 5 5
MI 10 10
CAD 31 30
Congestive heart failure 14 14
Renal failure*
Mild-moderate 13 13
Severe, no dialysis 5 5
Severe, dialysis dependent 2 2
Hypertension 74 72
Diabetes mellitus 11 11
Chronic pulmonary disease 32 31
Stroke 11 11
Cigarette smoking 63 62
Previous cardiac, thoracic aortic, 46 45
or vascular surgery
Previous thoracotomy (all reasons) 46 45
NYHA functional classification
NYHA I 40 39
NYHA II 41 40
NYHA III 21 20
NYHA IV 1 1
Not open (thoracotomy) surgical candidate 62 60
MI, Myocardial infaraction; CAD, coronary artery disease; NYHA, New York
Heart Association.
*Mild-moderate renal failure was defined as a creatinine concentration of 1.3
to 2.3 mg/dL (115-203 m mol/L) and severe renal failure as a serum creatinine
concentration of 2.4 mg/dL (212 m mol/L).
Table II. Preoperative aneurysm characteristics
No. of patients
Etiology
Atherosclerotic/degenerative 64
Aortic dissection 8
Trauma 8
Penetrating ulcer 10
Other* 13
Size of aneurysm (mm, mean ± 1 SD)
Main aneurysm (n = 103)
Aneurysm length 86 ± 50 (range 10-220)
Aneurysm diameter 62 ± 13 (range 40-110)
Proximal neck diameter 31.9 ± 4.0 (range 20-45)
Distal neck diameter 31.7 ± 3.8 (range 22-40)
Secondary aneurysm (n = 6)
Aneurysm length 80 ± 58 (range 35-190)
Aneurysm diameter 68 ± 24 (range 50-110)
Proximal neck diameter 30.3 ± 6.0 (range 24-38)
Distal neck diameter 29.7 ± 6.4 (range 22-38)
*Other: Mycotic (active in 1, healed in 1), anastomotic (n = 8), intramural
hematoma (n = 3).
had a stent-graft repair in which other surgeons at our institu-
tion were involved (n = 16) or at other institutions (n = 5) by
one of us (M.D.D.) and were excluded from this analysis.
The preoperative aneurysm data, including etiology and
size characteristics, are detailed in Table II. In 6 patients, a
second (separate) descending thoracic aortic aneurysm was
treated at the same procedure with an additional stent-graft.
The average interval from stent-graft insertion to hospital dis-
charge was 8 days (±6.5 days [±1 SD]; range 0-42 days). The
median stay was 6 days, with one quarter of patients dis-
charged on or before postoperative day 4 and one quarter on
or after day 10. Some of this inpatient time was dedicated to
completion of the protocol-mandated postprocedure imaging
studies and optimizing renal function. The mean time spent in
the intensive care unit was approximately 3 days.
The average stent-graft diameter was 3.5 cm (range 2.4-4.5
cm), and the average device length was 10.5 cm (range 4.5-
22.5 cm). The femoral artery was the most common site for
insertion (60 patients, or 58%), and the iliac artery was used
in 9 cases (9%). Two patients undergoing simultaneous repair
of an ascending aorta and arch aortic aneurysm or coronary
artery bypass grafting had the stent-graft inserted through the
transverse aortic arch in an antegrade manner with CPB and
profound hypothermic circulatory arrest. A retroperitoneal
approach to the infrarenal abdominal aorta was necessary to
introduce the device in 31 patients (30%); access was gained
through the native aorta in 10 of these patients, a previously
implanted abdominal aortic tube graft in 2, and a concomi-
tantly inserted aortic graft in 19 (18%). The endovascular pro-
cedure required placement of more than 1 stent-graft unit to
treat the aneurysm adequately in 34 patients, or 33%. Twenty-
six patients had 2 stent-grafts coaxially placed, 7 patients
required deployment of 3 devices, and in 1 patient it was nec-
essary to insert 4 devices. In 3 patients, the endovascular pro-
cedure for a descending thoracic aortic aneurysm was per-
formed after previous surgical placement of an elephant trunk
as part of arch aneurysm repair, that is, the dangling elephant
trunk graft functioned as the proximal landing zone. The
details of this combined approach have been previously
reported.22 In 1 of these patients, the stent-graft was not actu-
ally deployed. In this case, the delivery sheath could not be
advanced into an appropriate position within the elephant
trunk; further efforts to introduce the delivery sheath culmi-
nated in rupture of the proximal descending thoracic aorta,
which mandated immediate surgical conversion.
In 8 patients, the proximal neck between the left subclavian
artery and the aneurysm was judged to be too short or other-
wise inadequate to allow a competent seal between the graft
material and the aortic wall. In 3 patients the left subclavian
artery was transposed to the left common carotid artery, and
in 5 patients a left common carotid artery–left subclavian
bypass graft was implanted to create a suitable proximal
stent-graft landing zone before stent-graft deployment. The
proximal and distal locations of the stent-graft landing zones
are detailed in Table III. Stent-graft coverage of the inter-
costal arteries from the level of the ninth through the twelfth
thoracic vertebral bodies was necessary in 18 patients.
Coverage of more than 1 pair of intercostal arteries within
this segment, which is traditionally deemed critical for a
spinal cord perfusion, occurred in 44 cases.
The follow-up protocol included arteriography and spiral
CT imaging either before hospital discharge or within 5 days
of the initial procedure. Subsequently, spiral CT scans were
performed 6 months after stent-graft placement and yearly
thereafter. Patients underwent follow-up arteriography only if
they had symptoms or CT evidence of a perigraft leak
(endoleak) or other stent-graft abnormality.
Definitions and statistical analysis. Early mortality and
morbidity included events occurring both in the hospital and
after discharge, if they happened within 30 days. Patient
information was compiled from retrospective chart review
and by contacting the patient or family members or the treat-
ing physicians. Cause of death was determined from exami-
nation of death certificates, medical records, and, when avail-
able, autopsy reports. Current follow-up status was obtained
between October 1997 and March 1998 and was 100% com-
plete; follow-up averaged 1.8 ± 1.3 years, with a maximum of
5.3 years.
Many of the preoperative and intraoperative parameters
inspected in the risk analyses are listed in Tables I to III.
Additional variables were also entered and are listed in
Appendix 1. When necessary, the hazard associated with each
possibility was individually determined, and then the vari-
ables were ranked in logical order and entered into the multi-
variable Cox model analyses. Clinical outcome events of
interest were defined thus: (1) treatment failure 1—all early
deaths, late deaths related to complications arising in the
treated aortic segment, endoleak, and need for subsequent
intervention (catheter-based or surgical) in the treated aorta;
(2) treatment failure 2—all of the above plus any sudden,
unexplained late deaths. Nonfatal and fatal complications
were subdivided into stent-graft–related and non-stent-
graft–related complications; individual patients could have
both types of nonfatal complications but could have only 1
type of fatal complication. To characterize how well the
endovascular stent-graft worked, the following therapeutic
definitions were used: (1) primary success, complete throm-
bosis of the aneurysm at the time of the first postoperative CT
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Table III. Location of proximal and distal aortic
stent-graft “landing zones” in 103 patients
Proximal Distal 
stent-graft stent-graft 
landing zone landing zone
Distal arch* 8 3
Proximal third, descending aorta 71 15
Mid third, descending aorta 19 31
Distal third, descending aorta 4 40
Supraceliac abdominal aorta 0 13
*Distal arch was defined as the aortic segment from the left common carotid
artery to 20 mm distal to the left subclavian artery.
scan; (2) secondary success, endoleak with subsequent
thrombosis; (3) unsuccessful, no secondary intervention
attempted; (4) unsuccessful, persistent endoleak after sec-
ondary intervention; (5) endoleak with spontaneous thrombo-
sis; and (6) aorta and/or stent-graft replaced or excluded.
SPSS for Windows (version 6.1, SPSS Inc, Chicago, Ill) was
used for all statistics. Continuous data are reported as mean ±
1 standard deviation (SD). Important ratios, for example,
operative mortality rate, are reported with 70% confidence
limits (±70% CL). The Cutler-Ederer life table method was
used to generate actuarial estimates, which are reported as ±1
standard error (SE). In the multivariable Cox proportional
hazards model, statistical significance was inferred if P < .03,
and the b coefficients from the equation are reported. The
magnitude of the clinical impact of predictive covariates on
outcome events in the Cox model is reported as an indicator
of relative risk, eb , but this can only be strictly interpreted for
dichotomous covariates. If certain covariates made the model
unstable or had tremendous clinical impact, then the model
was re-run without this variable, and the results are reported
separately.
Results
The results were compiled and analyzed according to
the “intent-to-treat” principle. As such, the 1 patient
described above who actually did not receive an
endovascular stent-graft is included in this analysis; she
is considered to have had a stent-graft–related death
and treatment failure.
Early mortality. Including this patient (death attrib-
uted to aneurysm rupture), the operative mortality rate
was 9% ± 3%. The other causes of early death were
stroke due to intracerebral hemorrhage in 1, sepsis in 2,
multisystem organ failure in 1, pulmonary insufficiency
in 1, cancer in 1 (the patient had a contained aortic rup-
ture caused by tumor invasion), hemorrhage in 1, and
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Table IV. Parameters identified in the multivariable
Cox model analysis to be associated with a higher
probability of sustaining selected early and late post-
operative adverse outcomes
b P value e b
Early death (P = .0011)
MI +2.1 .04 8.1
Stroke +2.2 .01 9.1
No. of S-G units deployed –6.1 .0003 .0022
Etiology +1.2 .02 3.3
Treatment failure 1 (P = .0155)
(Earlier) operative year –.32 .017 .73
Treatment failure 2 (P = .006)
(No) CAD –.86 .034 .42
(Earlier) operative year –.36 .007 .70
All deaths (P = .003)
Not open surgical candidate +2.0 .006 7.6
CPB +2.9 .02 17.4
Without CPB covariate (P = .003)
Not open surgical candidate +1.7 .008 5.2
Late deaths (P = .0000)
(Larger) aneurysm diameter +.06 .006 1.1
(Larger) S-G proximal LZ diameter +.2 .035 1.2
CPB +3.0 .0207 19.5
(Older) age +.10 .0107 1.1
Without CPB covariate (P = .0001)
(Larger) aneurysm diameter +.06 .0024 1.07
(Larger) S-G proximal LZ diameter +.21 .023 1.2
(Older) age +.08 .022 1.1
Nonfatal S-G complications (P = .0007)
(More proximal) distal LZ site –.38 .03 .68
Move LSCA +.40 .03 1.5
Elephant trunk +2.2 .006 8.9
(Earlier) operative year –.28 .039 .75
Surgical access site +.41 .0018 1.5
Without elephant trunk covariate (P = .0035)
Move LSCA +.44 .011 1.6
(Earlier) operative year –.30 .032 .74
Surgical access site +.31 .014 1.4
Nonfatal complications (P = .0000)
Angina –1.01 .025 .36
MI +2.9 .0000 17.2
Surgical access site +.80 .0001 2.2
Etiology +1.08 .016 3.0
Fatal S-G complications (P = .0009)
Stroke +3.4 .054 30.9
(Larger) distal S-G LZ diameter +.66 .025 1.9
More distal) S-G proximal LZ +.76 .006 2.1
Table IV. Continued
b P value e b
Fatal complications (P = .0007)
Stroke +2.3 .009 10.0
(More proximal) S-G distal LZ –.75 .039 .47
CPB +5.6 .0005 269
Etiology +1.7 .007 5.5
Without CPB covariate (P = .0013)
Stroke +1.6 .02 4.9
Coil embolization of endoleak 
(P = .0000)
MI +2.1 .024 8.0
(Shorter) aneurysm length –.043 .005 .96
Move LSCA +1.4 .0000 4.0
Repeat stent-graft (P = .0124)
Surgical access site +1.3 .009 3.6
Surgical stent-graft removal (P = .0001)
(Smaller) S-G distal diameter –.18 .008 .84
S-G, Endovascular stent-graft; CAD, coronary artery disease; LZ, landing
zone of stent-graft; CPB, cardiopulmonary bypass; LSCA, left subclavian
artery; MI, myocardial infarction. The b coefficient is from the multivariable
equation and its sign indicates whether the relationship with the hazard of the
event is direct or indirect. The e b term reflects relative risk; a value of 1.0 cor-
responds to no change in probability of sustaining the event risk, values
greater than 1 indicate increased risk, and those less than 1 imply less risk.
These estimates of relative risk only apply strictly to dichotomous covariates
and need to be interpreted with caution in the case of categorical or continu-
ous covariates.
pulmonary embolism in 1 patient. Multivariable Cox
model analysis revealed that the presence of a prior
myocardial infarction (MI) increased the probability of
early death by 8-fold, and stroke increased the risk by 9-
fold (see Table IV). In the absence of a remote MI, the
30-day survival estimate was 92% ± 3%, whereas it was
79% ± 3% if the patient had had an MI; similarly, with-
out a preoperative stroke it was 93% ± 3% versus 71%
± 4%. Additionally, the need to use fewer stent-graft
units to exclude the aneurysm was associated with a
higher risk. Aneurysm etiology also influenced the early
death hazard: The “other etiology” category carried the
highest risk of death (3/13 = 23%), whereas it was 10%
in the 10 patients with a penetrating ulcer and 8% in the
64 patients with an atherosclerotic/degenerative
aneurysm.
Early postoperative morbidity. Major early postop-
erative complications included stroke in 7 patients (7%
± 3%), paraplegia/paraparesis in 3 (3% ± 2%), MI in 2
(2% ± 1%), and respiratory insufficiency in 12 (12% ±
3%). Table V lists the incidence of these and other early
morbid events, which occurred commonly. Surgical
conversion was necessary in only 1 case. In 3 cases the
stent-graft was deployed in the incorrect location,
termed stent-graft misdeployment. One patient had a
new, limited proximal aortic dissection.
Separate multivariable analyses were performed for
stroke, paraplegia, MI, and respiratory failure: The only
significant, independent determinant of stroke was the
use of CPB (b coefficient = 2.9, P = .01, eb = 17.9); this
strong influence of CPB was due to the fact that only 2
patients required CPB for insertion of the stent-graft
through the arch, and 1 of them had a mild cerebellar
stroke, yielding a 50% incidence. When the analysis
was run without the covariate CPB, no covariates
emerged as significant predictors of stroke. As one
would expect, the only predictor of MI was the pres-
ence of coronary artery disease (CAD). The risk of
paraplegia was higher according to surgical access site,
with an incidence of 7% in those who required access
via the abdominal aorta (2 of 29 patients). The third
case of paraplegia occurred in the sole patient who had
the stent-graft inserted via an old aorto-femoral bypass
graft limb. Even though not statistically significant in
the multivariable analysis, the paraplegia rate was 11%
± 7% (2/19) in those patients who underwent simulta-
neous surgical repair of abdominal aortic aneurysm and
stent-grafting of the descending thoracic aortic
aneurysm compared with 1% ± 1% for the 84 who did
not; the third individual who had paraplegia had under-
gone repair of an ascending aortic aneurysm previous-
ly. Therefore the paraplegia/paraparesis rate was 6% ±
4% among the 47 patients who either had had an
ascending aortic aneurysm repair before or had a coex-
istent ascending aortic aneurysm (3/47) versus 0%
(0/56) for the others. Finally, the risk of pulmonary
insufficiency was linked to the presence of CAD (eb =
3.5); furthermore, if the patient was judged not to be a
suitable candidate for an open operation, the risk of res-
piratory failure was 6-fold higher (eb = 6.1).
Early or late stent-graft endoleaks. An early
endoleak was documented by angiography or CT scan-
ning in 24% ± 4% of cases, mostly during the first year
of our experience. Primary success was achieved ini-
tially in 75 patients, or 73% ± 5%. Secondary success
was accomplished in 11 other cases; therefore com-
plete aneurysm thrombosis was eventually documented
in 86 patients (or 84% ± 4%). An early or late stent-
graft endoleak was not treated in 7 patients and persist-
ed after coil embolization in 2 others. Three individu-
als had endoleaks that spontaneously thrombosed. At
the time of this follow-up, 5 stent-grafts had been sur-
gically removed or excluded.
Overall and late survival. There were 14 late deaths
(MI in 2, documented ventricular tachyarrhythmia in 1,
sudden/unexplained in 6, stroke in 2 [thromboembolic
in 1 case], aneurysm rupture in 2, and respiratory fail-
ure in 1), in addition to the 9 early deaths. When all
patients are considered, the actuarial survival estimates
were 86% ± 4% at 6 months, 81% ± 4% at 1 year, and
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Table V. Early postoperative complications and mor-
tality among the 103 patients
Rate ±70% CL 
N (%) (%)
Early death 9 9 ±3
Paraplegia/paraparesis 3 3 ±2
MI 2 2 ±1
Pulmonary insufficiency 12 12 ±3
(± tracheostomy)
Stent-graft misdeployment 3 3 ±2
Initial stent-graft endoleak 25 24 ±4
Arterial injury/replacement 4 4 ±2
DVT/venous injury/PE 1 1 ±1
Gut ischemia/infarction 1 1 ±1
Acute renal failure (± dialysis) 5 5 ±2
Distal arterial thromboembolism 2 2 ±1
New aortic dissection (proximal) 1 1 ±1
Hemorrhage (local) 5 5 ±2
Hemorrhage (systemic/coagulopathy) 2 2 ±1
Wound infection 3 3 ±2
Other unrelated vascular operation 1 1 ±1
Other unrelated interventional procedure 4 4 ±2
MI, Myocardial infarction; DVT, deep venous thrombosis; PE, pulmonary
embolism; 70% CL, 70% confidence limits.
73% ± 5% after 2 years (Fig 2). As shown in Table IV,
the only significant, independent determinants of all
deaths were “not open surgical candidate” (eb = 7.6)
and CPB (eb = 17.4). To examine whether other pre-
dictors would emerge if the dominating covariate CPB
(used in only 2 patients) was eliminated, re-running the
Cox model without CPB yielded only “not open surgi-
cal candidate” (eb = 5.2), that is, the risk of death was
5-fold higher. If an individual had been judged not to
be a suitable candidate for an open operation, the sur-
vival estimate was 60% ± 7% at 2 years compared with
91% ± 5% at 1 year (Fig 2, B) for the others.
Focusing just on the 14 late deaths, the actuarial sur-
vival estimates were 89% ± 4% at 1 year and 80% ±
5% at 2 years. Interestingly, analyzing late deaths by
means of the Cox multivariable model revealed 3 other
determinants of late death in addition to CPB—larger
aneurysm diameter, larger proximal stent-graft landing
zone diameter, and older age. As was seen for all
deaths, the influence of CPB, necessary in only 2 cases,
was disproportionally large (eb = 19.5); if CPB was
excluded from the analysis, the same 3 other covariates
remained, the goodness of fit was not substantially dif-
ferent, and the relative risks were similar. These other 3
predictors (larger aneurysm diameter, larger stent-graft
proximal landing zone diameter, and older age), how-
ever, had only modest effects on the risk of late death,
raising the hazard by only 10% to 20% (see Table IV).
Treatment failure. As noted earlier, 2 definitions of
treatment failure were used. Thirty-six patients sus-
tained treatment failure 1, and the only multivariable
determinant of treatment failure 1 was earlier operative
year (eb = 0.73). Since sudden deaths could also be due
to aneurysm rupture, all sudden, unexplained late
deaths were considered in the definition of treatment
failure 2, which added 2 patients.
Inasmuch as the numbers of patients sustaining treat-
ment failures 1 and 2 were similar, only treatment fail-
ure 2 will be emphasized. Fig 3 illustrates the actuarial
freedom from treatment failure 2 for all 103 patients.
Most of these adverse events occurred early (average
84 days). The estimate of patients free from treatment
failure 2 was 68% ± 5% at 30 days, 65% ± 5% at 1
year, and 53% ± 10% at 3.7 years. The significant,
independent predictors of treatment failure 2 were the
absence of CAD (eb = 0.42) and earlier operative year
(eb = 0.70). The actuarial estimate of freedom from
treatment failure 2 for patients without CAD was 53%
± 7% at 18 months compared with 63% ± 14% at 3.5
years for those with CAD. The influence of earlier
operative year was more modest, reflecting only a 30%
increased hazard.
Late complications. Complications were catego-
rized according to whether they were directly related to
the stent-graft or the operative procedure and whether
they were fatal or nonfatal. Early and late complica-
tions were considered together in this analysis, and
patients could have more than 1 complication. The pre-
dictors of need for coil embolization of stent-graft
endoleaks, repeat stent-grafting, and surgical removal
or bypass of the original stent-graft were also exam-
ined, as they are indicative of the durability of the stent-
graft procedure.
Nonfatal stent-graft complications. Forty-nine nonfa-
tal stent-graft complications occurred in 39 patients,
including stent-graft misdeployment (n = 3), stent-graft
removal (n = 1), initial endoleak (n = 25), late endoleak
(n = 1), new aortic dissection (n = 1), arterial
injury/replacement (n = 2), stroke (n = 2), paraple-
gia/paraparesis (n = 3), distal arterial thromboem-
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Fig. 2. A, Actuarial curve depicting overall survival estimates
for all 103 patients. B, Survival estimates according to whether
the patient was judged not to be a reasonable candidate for open
repair. SE, Standard error of the estimate.
bolism (n = 1), gut ischemia/infarction (n = 1), infec-
tion (n = 2), other aortic reoperations (n = 3), and
catheter-based interventional procedures (n = 4),
including stenting of the left subclavian artery. The
most common complication was initial endoleak, and
this was confined for the most part to the early phase of
this series during our initial learning experience. On the
other hand, no patient had stent-graft migration or dis-
tal embolization. Most of these stent-graft complica-
tions occurred during the first postoperative year; in
actuarial terms, 61% ± 5% of patients were free from a
nonfatal stent-graft complication at 1.2 years, as were
52% ± 9% at 3.7 years (Fig 4, A). Table IV shows that
the significant, independent determinants of nonfatal
stent-graft complication were more proximal distal
stent-graft landing zone (eb = 0.68), bypassing the left
subclavian artery (eb = 1.5, or a 50% increase in risk),
use of an elephant trunk graft for the proximal landing
zone (eb = 8.9), (earlier) operative year (eb = 0.75, a
25% higher risk), and more difficult surgical access
sites (eb = 1.5, or a 50% higher risk). Inasmuch as only
3 patients underwent attempted insertion of the stent-
graft into an elephant trunk graft, the multivariable
analysis was re-run without this covariate; the other 3
determinants remained (see Table IV). If the distal
stent-graft landing zone was in the proximal descend-
ing aorta, for example, the shortest stent-grafts, only
17% ± 13% of these 15 patients were free from a non-
fatal stent-graft complication at 6 months, compared
with 50% to 69% of patients in whom the distal land-
ing zone was located more distally (Fig 4, B). As illus-
trated in Fig 4, C, the 5 patients who required a left sub-
clavian artery–left carotid artery bypass graft had an
estimate of freedom from a nonfatal stent-graft compli-
cation of only 20% ± 18% at 6 months, whereas it was
100% free for the 3 patients who underwent carotid
artery–left subclavian artery transposition and 53% ±
10% at 3.5 years for the 95 individuals who did not
require the left subclavian artery to be moved.
Subdivided according to access site, these complica-
tions were seen less frequently in those who required
native femoral arterial access (19/60 = 32%); the inci-
dence of nonfatal stent-graft complications was 41% in
patients requiring access via the abdominal aorta and
56% (5/9) in those with iliac artery access.
Nonfatal complications. Twenty-four patients had a
total of 31 nonfatal complications that were not direct-
ly related to the stent-graft. These included a new (dis-
tal) aortic dissection (n = 1), stroke (n = 1), deep
venous thrombosis or pulmonary embolism (n = 1),
distal arterial thromboembolism (n = 1), gut
ischemia/infarction (n = 1), MI (n = 2), renal failure (n
= 5), excessive local or systemic bleeding (n = 5),
wound infection (n = 1), pulmonary failure (n = 6), tra-
cheostomy (n = 3), unrelated aortic reoperation (n = 3),
and other catheter intervention (n = 1). The life table
estimate of freedom from a nonfatal complication was
72% ± 6% at 2.8 years. Table IV lists the 4 covariates
that had an impact on the risk of sustaining a nonfatal
complication: angina, MI, more difficult surgical
access site, and etiology. The presence of a preopera-
tive MI markedly influenced the probability of a non-
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Fig 3. Actuarial estimate of the freedom from treatment failure 2 (see text for definition) for all 103 patients. SE,
Standard error of the estimate; TF#2, treatment failure 2.
fatal complication: MI was associated with a 17-fold
increase in hazard; similarly, the absence of angina was
linked with a substantially lower risk. Inserting the
stent-graft through the native femoral artery was asso-
ciated with the lowest incidence of nonfatal complica-
tions. With respect to cause of the aneurysm, the high-
est rates of nonfatal complications were seen in the
atherosclerotic/degenerative and aortic dissection cate-
gories.
Fatal stent-graft complications. A total of 5 fatal
stent-graft complications occurred in 4 patients. These
events included rupture of the treated aneurysm (n = 2),
stent-graft erosion into the esophagus (n = 1), arterial
injury necessitating graft replacement (n = 1), and
excessive local bleeding (n = 1). Overall, 96% ± 2% of
patients were free from a fatal stent-graft complication
at 9 months. Multivariate analysis revealed that a pre-
operative stroke (eb = 30.9) tremendously increased the
likelihood of such a fatal complication. Other predic-
tors that approximately doubled the hazard were larger
distal stent-graft landing zone diameter (eb = 1.9) and
more distally located stent-graft proximal landing zone,
that is, stent-grafts deployed starting farther down the
descending thoracic aorta (eb = 2.1).
Fatal complications. Nine patients had a total of 12
early or late fatal complications. These serious compli-
cations included stroke (n = 3), pulmonary embolism (n
= 1), MI (n = 1), renal failure necessitating dialysis (n
= 1), infection (n = 1), excessive local bleeding (n = 1),
and pulmonary failure (n = 4). As seen before, most of
these adverse events occurred in the early postoperative
period; in actuarial terms, 90% ± 3% of patients were
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Fig 4. A, Incidence of nonfatal stent-graft–related complications among all 103 patients. B, Nonfatal stent-graft
complications as a function of the location of the distal stent-graft landing zone. C, Nonfatal stent-graft compli-
cations subdivided on the basis of manipulation of the left subclavian artery. SE, Standard error of the estimate;
S-G, stent-graft; Abd Ao, abdominal aorta; DsThAo, descending thoracic aorta; LSCA, left subclavian artery;
LCCA, left common carotid artery.
estimated to be free from a fatal complication at 9
months. Preoperative stroke increased the risk markedly
(eb = 10.0). It was about 50% higher for patients who
required a shorter stent-graft (more proximal stent-graft
distal landing zone) (eb = 0.47), inordinately higher if
CPB was necessary, and also higher according to etiol-
ogy (Table IV). Patients with atherosclerotic or “other
etiology” aneurysms (see Table II) had the highest risk
of a fatal complication, whereas no patient with a pen-
etrating ulcer, aortic dissection, or a traumatic false
aneurysm had one. If the CPB covariate was excluded,
the only predictor of a fatal complication was stroke (eb
= 4.9), which increased the chance of a fatal complica-
tion nearly 5-fold (see Table IV).
Ten patients required coil embolization for closure of
stent-graft endoleaks at an average of 4.2 months after
the operation; nine were proximal leaks, and 1 was a
distal leak. Three years after the operation 87% ± 5%
of patients were free from coil embolization (Fig 5).
Interestingly, one significant, independent predictor
was MI (e b = 8.0); the other risk factors—shorter
aneurysm length (eb = 0.96) and the need to move the
left subclavian artery (eb = 4.0)—were more intuitively
plausible. That is, treating shorter aneurysms and the
necessity to “create” a longer proximal stent-graft land-
ing zone portended more endoleaks that necessitated
coil embolization.
Only 5 patients ultimately required surgical removal
or exclusion of the stent-graft, in 2 of them when the
treated thoracic aortic aneurysm had leaked or rup-
tured. One patient counted here (intent-to-treat princi-
ple) never actually received a stent-graft, being the soli-
tary surgical conversion case. One other individual
with a chronic type A aortic dissection had enlargement
of the arch component and received an extra-anatomic
graft from the old ascending aortic graft to the abdom-
inal aorta with exclusion of the entire descending tho-
racic aorta. (The descending thoracic aorta contained
the stent-graft, which had been inserted for rupture of
the false lumen.) The actuarial estimate of freedom
from stent-graft removal was 86% ± 9% at 3.7 years
(Fig 5). Unexpectedly, (smaller) stent-graft distal diam-
eter emerged as the sole predictor of a slightly higher
probability of requiring subsequent operation to
remove the stent-graft (eb = 0.84, or a 16% higher risk,
Table IV).
Fate of the aneurysm. This important question
needs to be answered to determine whether stent-graft
treatment of descending thoracic aortic aneurysms is
efficacious over the long term; on the other hand,
obtaining serial CT scans has been difficult, because
few of these patients live locally. Nonetheless, in 1996
a limited analysis was performed in 85 of the initial
patients who received a stent-graft. Among these, 63
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Fig 5. Actuarial incidence of the freedom from various stent-graft interventions, including need for coil emboliza-
tion, repeat stent-graft insertion, and surgical removal* or exclusion of the initial stent-graft. SE, Standard error
of the estimate; S-G, stent-graft. *The first patient to receive a stent-graft had the device removed at the time of
emergency reoperation for contained rupture (previous coarctation repair 20 years before the stent-graft) 62
months later. This event is not indicated on the graph for stent-graft removal because he was the only remaining
patient at risk at that time.
had both a preoperative and an early (<10 days) post-
operative CT scan; the average aneurysm diameter
before stent-grafting was 59 mm, and it was 60 mm on
the early postoperative scan. A subgroup of 23 patients
had a subsequent late CT (average 1.1 years) available
for comparison. With the use of a threshold of 3-mm
increase or decrease to indicate a change in maximal
aneurysm diameter, 6 of the 23 (26%) had an increase
in size (3 with no demonstrable endoleak leak, 2 of 8
with a treated leak, and 1 of 2 with a persistent leak),
6 (26%) had no change (3 with no leak, 2 of 8 with a
treated leak, and 1 of 2 with a persistent leak), and 11
(48%) had a decrease in aneurysm size (7 with no
demonstrable endoleak leak, 4 of 8 with a treated
leak).
Comparison with results in the entire patient
series. During this time period an additional 21 patients
received a stent-graft by one of us (M.D.D.), yielding a
grand total of 124 patients. Some of these cases were
included in previous publications.16,21 Among these
other 21 patients, 1 additional case of paraplegia, 1
other stroke, and 1 additional early death occurred.
Therefore the overall incidence of these adverse events
in the entire series of 124 patients was 4 (3% ± 2%) for
paraplegia, 8 (7% ± 2%) for stroke, and 10 (8% ± 3%)
for early death; these figures are not different from the
results reported herein for our selected 103 patients.
Discussion
Thoracic aortic aneurysm is a life-threatening condi-
tion with an estimated incidence of approximately 6
cases per 100,000 person-years.23 Although the condi-
tion is relatively uncommon, the number of patients
with thoracic aortic aneurysms is increasing, presum-
ably because of the increase in life expectancy of the
population and the availability of improved diagnostic
modalities. Untreated thoracic aortic aneurysms are
likely to expand over time and eventually rupture.
Approximately 50% of patients with descending aortic
aneurysms are free of symptoms when the initial diag-
nosis is made because thoracic aortic aneurysms rarely
produce symptoms until progressive growth causes
compression of adjacent structures or rupture.24
Several reports have estimated that the risk of rupture
in patients with thoracic aortic aneurysms ranges from
46% to 74%; therefore the actuarial 5-year survivals
are very low, between 9% and 13%.23,25 The risk of
rupture of thoracic aortic aneurysms mandates consid-
eration of surgical treatment in all individuals who are
suitable candidates for operation. Although no precise-
ly defined, objective criteria prevail, operative repair is
strongly recommended for any symptomatic aneurysm
or any aneurysm that exceeds 2 times the transverse
diameter of an adjacent normal-caliber aortic segment
or is 6 cm in diameter or larger. Elective surgical graft
replacement is the traditional approach for the treat-
ment of these patients and is currently associated with
5-year survivals ranging from 70% to 79%.1,4,26,27
Transluminally placed endovascular stent-grafts offer
an alternative approach to treatment that is potentially
less invasive, less expensive, and less risky than stan-
dard open operative repair. Theoretically, endovascular
repair of thoracic aortic aneurysms with stent-grafts will
have lower morbidity and mortality rates than conven-
tional surgical approaches because it avoids thoracoto-
my and aortic crossclamping. The operative mortality in
our series was 9%, which is not lower than the average
overall (emergency and elective) risk of 11% reported
for surgical repair1,4,26-28; however, in the context of the
specific patient population described herein, which
included 16% of patients being treated on an emergency
basis and 60% not being considered to be reasonable
operative candidates, we believe that this early mortali-
ty rate is quite acceptable. Although the placement of
fewer stent-graft units to exclude the aneurysm was
associated with a higher risk of mortality, all 9 patients
in this group received a single stent-graft and died of
other, unrelated causes (eg, intercerebral hemorrhage,
sepsis, multisystem organ failure, pulmonary insuffi-
ciency, cancer, hemorrhage, and pulmonary embolism).
The incidence of most serious postoperative morbid
events, including paraplegia/paraparesis (3%), MI
(2%), and respiratory insufficiency (12%), was approx-
imately what would be expected after open surgical
repair. Of note, the incidence of paraplegia with the
stent-graft procedure was not substantially different
from that documented for open operative treat-
ment.1,4,26-28 Conversely, the 7% occurrence of stroke
in this series was disappointingly high. Although dif-
ferent causes (excessive anticoagulation, catheter, or
surgical manipulations in the aortic arch, carotid, or
subclavian arteries) were responsible for the strokes, it
is intuitive that insertion of a large (24F-26F), relative-
ly stiff delivery sheath into and across the origins of the
brachiocephalic and carotid arteries within a diseased
aortic arch is not desirable. Currently, the availability
of lower profile, over-the-wire flexible delivery
catheters allows stent-graft deployment without an
overlying introducer sheath, which should minimize
trauma to the aortic arch and the potential for cerebral
embolization. Smaller stent-graft delivery systems also
require less anticoagulation during the procedure,
which may reduce the frequency of bleeding complica-
tions, including cerebral hemorrhage.
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Since the initial popularization of endovascular stent-
graft placement for the treatment of abdominal aortic
aneurysms, perigraft leaks (endoleaks) have loomed as
the Achilles’ heel of this new technique. In the current
series, an early endoleak was identified in 24% of
cases. This rate appears alarmingly high; however, the
majority occurred during the first year of our experi-
ence when predictive anatomic criteria for procedural
success involving neck length, shape, angulation, and
other factors were not yet identified. At that time, we
accepted “benign appearing” minimal endoleaks on the
initial CT scan, which was a mistake. Similarly, in the
early days of our learning curve we did not fully appre-
ciate the need to have back-up stent-graft devices avail-
able and, consequently, were not technically prepared
to address unanticipated problems resulting from inad-
vertent errors in sizing and/or imprecise device deploy-
ment. Later on, additional stent-graft devices were
coaxially deployed in such situations to extend graft
coverage and successfully isolate the aneurysm from
aortic blood flow.
Transcatheter coil embolization of the perigraft
tract(s) causing the endoleak was performed in 10
patients.29 The majority of these procedures were car-
ried out before hospital discharge. In 9 cases, the leak
was at the proximal margin of the device; in most it was
located adjacent to the left subclavian artery or left
common carotid artery, where its obliteration by proxi-
mal placement of an additional stent-graft extension
was not feasible. Occasionally, balloon expansion of
the initial stent-graft was performed before coil
embolization. Balloon expansion alone successfully
occluded the endoleak in only 1 case. Placement of an
uncovered stent across the proximal aspect of the stent-
graft and over the left subclavian and/or left common
carotid origins was not attempted. One endoleak was
located at the distal margin of the stent-graft. However,
no cases of retrograde leak into the aneurysm sac from
intercostal collateral flow were observed, as have been
described in the abdominal aortic stent-graft experience
with retrograde flow into the aneurysm sac via lumbar
or inferior mesenteric arteries. The predominance of
proximal leaks most likely reflects the use of a semi-
rigid, segmented device that is incapable of accommo-
dating to the curved anatomy of the distal aortic arch to
secure a tight circumferential seal. Aortography and CT
scans after coil embolization documented thrombosis
of the aneurysm sac in 8 of the 10 cases; however, the
long-term efficacy of this transcatheter embolization
approach to the management of stent-graft endoleaks
remains unknown.30
Survival is of key importance when evaluating any
new alternative therapy for patients with aortic
aneurysms. In this series there were 23 deaths. The
actuarial survival estimates illustrated in Fig 2 are not
dissimilar from those reported in large recent surgical
series.1,4,26-28 The only relevant determinant of all
deaths was the surgical judgment decision that a patient
was “not an open surgical candidate.” The risk of death
was 5-fold higher in this subset, and their survival esti-
mate was 60% at 2 years, compared with 91% at 1 year
for those who were deemed appropriate surgical candi-
dates (Fig 2, B). Although this raises the philosophical
question of whether endovascular stent-graft therapy
should even be offered to patients deemed not to be
suitable candidates for an open operation, because of
the poor postoperative survival statistics, the actuarial
estimates presented in Fig 2 compare favorably with
the natural history survival data for patients with tho-
racic aortic aneurysms.7,23
Treatment failure 2 occurred in 38 patients. Most of
these adverse events occurred in the early postoperative
period (Fig 3). One of the 2 significant independent
predictors of treatment failure was “earlier operative
year,” which reflects our learning how to use the device
and our increasing ability over time to select which
patients were best suited for the stent-graft procedure
based on individual anatomy, including aneurysm loca-
tion and neck morphology, aneurysm etiology, and vas-
cular access for device introduction. For example,
many of the treatment failures and some of the fatal
stent-graft complications occurred in patients who had
a very tortuous aorta; in retrospect, these patients did
not have a satisfactory, tubular distal neck above the
celiac axis. This point may be related to the findings
that larger aneurysm diameter and larger stent-graft
proximal landing zone diameter were significant pre-
dictors of late death, and patients with the more distal-
ly located stent-grafts had a higher incidence of fatal
stent-graft complications (Table IV). Second, patients
with chronic aortic dissections clearly are not good
candidates for stent-grafts, because the distorted, non-
circular true or false lumina do not lend themselves to
a good circumferential friction seal. On the other hand,
certain patients with acute type B aortic dissections
may be suitable, as was the case in 4 patients in this
series. It is clear that the best candidates for stent-graft-
ing are those with fairly localized aneurysms (or anas-
tomotic false aneurysms), including patients with giant
penetrating ulcers. Surprisingly, the 1 patient with a
ruptured aneurysm with active mycosis (C. septicum,
with a colon carcinoma) did not become reinfected;
however, in general, surgery should be avoided in
patients with any active, infectious process.
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In terms of late complications, 49 nonfatal stent-graft
complications occurred in 39 patients, most during the
first postoperative year. One half of these (n = 25) were
initial endoleaks. More proximal distal stent-graft land-
ing zone (eg, shorter stent-grafts), bypassing the left
subclavian artery, and earlier operative year were all
significant predictors of nonfatal stent-graft complica-
tions. The first 2 were most likely associated with the
incidence of endoleaks, stroke, and stent-graft misde-
ployment related to our initial lack of full appreciation
of the anatomic and technical challenges portended by
distal arch aneurysms, which involve more catheter
manipulations in the aortic arch and/or surgical transfer
of the left subclavian artery. The frequency of
endoleaks with this type of aneurysms is accentuated
by the inability of these semirigid, segmented Z-stent
prostheses to conform well to the curved geometry of
the involved aorta and form a tight seal against the aor-
tic wall within the aneurysm neck.
Currently, the improved, more flexible commercially
developed stent-graft systems that are associated with
less traumatic delivery and more precise targeting
should lower the frequency of these complications. In
theory, more refined devices in the future may actually
permit the stent-graft to be retrieved or constrained
after partial deployment. Finally, additional experience
and enhanced understanding of the technical limita-
tions and anatomic constraints associated with the pro-
cedure should facilitate more appropriate selection of
patients, which should translate into better success
rates. In this context, Fig 1 shows that the number of
stent-graft procedures actually fell somewhat in the
later 2 years of this study. This is due to several factors,
but the chief cause was the more restricted patient
selection criteria pivoting on anatomic and general con-
siderations, for example, not offering stent-grafts to
elderly patients who had other debilitating medical dis-
orders, which limited their life expectancy, and contin-
uing to prefer open surgical repair in younger, low-risk
surgical candidates because of the unknown very long-
term durability of the endovascular approach.
Thirty-one nonfatal, non-stent-graft–related compli-
cations were observed. The variety, severity, and fre-
quency of these events were not unexpected given the
patient substrate and type of aneurysms that were treat-
ed. Angina, MI, more difficult surgical access for stent-
graft introduction, and etiology adversely affected
these events. Five fatal stent-graft complications
occurred in 4 patients. Three of these events occurred
during the operation, including rupture of the descend-
ing aorta in 1 patient and avulsion of the iliac artery
plus excessive bleeding during introduction of the
delivery sheath in another patient. Both of these com-
plications are potentially avoidable in the future with
smaller diameter, flexible stent-graft delivery catheters
that do not require introduction of a large, relatively
rigid introducer sheath. The 2 remaining fatal stent-
graft complications occurred in the late postoperative
period and were related to aneurysm rupture. In 1 case,
a patient with a late endoleak (unknown to us) had con-
tinued aneurysm enlargement that culminated in rup-
ture into the esophagus; in the other patient, erosion
and infection of the stent-graft resulted in an aorto-
esophageal fistula. Thus fatal aneurysm rupture
occurred in 2 patients, or 2%. As reflected in Fig 5,
intense serial imaging surveillance is required to detect
any endoleaks that might occur around the stent-graft,
such that interventional or surgical therapy can be car-
ried out. Although the need for coil embolization,
repeat stent-grafting, and definitive surgical excision of
the stent-graft certainly detract from the long-term
“durability” of this approach, they can be lifesaving.
Study limitations. Several factors exist that mandate
continued caution in the interpretation of these results.
For example, the lack of serial CT scans postoperatively
at many points in time for all patients limits what can be
said about whether one or both aneurysm necks might
slowly dilate over the years, which conceivably could
be associated with the appearance of late endoleaks.
Such information would also allow one to comment on
whether or not the aneurysm sac becomes smaller over
time as the thrombus becomes transformed into fibrous
scar tissue. Second, the absence of autopsy information
in all patients who died makes it difficult to state with
certainty whether the endovascular stent-graft failed to
prevent aneurysm rupture. To err on the side of being
conservative, we have included all late sudden unex-
plained deaths in the treatment failure 2 category to
reflect this possibility; interestingly, this added only 2
patients to the total, implying that most of these patients
had already been documented to have a stent-
graft–related problem, that is, had qualified as meeting
the treatment failure 1 criteria. Our postoperative fol-
low-up can still only be considered to be early to medi-
um term; 5- to 10-year results in larger numbers of
patients will be required to assess the truly long-term
effectiveness of this method of endovascular treatment.
Finally, until we have more confidence in this endovas-
cular approach beyond 5 years, it is probably prudent
not to offer a stent graft to younger patients at low sur-
gical risk, because the long-term durability of open sur-
gical graft replacement remains the “gold standard” of
care, and the likelihood of a good surgical outcome in
these individuals is relatively good.
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Appendix 1. Additional preoperative and
intraoperative variables not listed in Tables I to III
examined in multivariate risk analyses
Operative year
“Not an open surgical candidate”
Aortic rupture
Emergency operative status
Surgical access route
CPB
Simultaneous repair of ascending aortic aneurysm
Left subclavian artery moved
Elephant trunk proximal landing zone
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Length of the stent-graft
Proximal diameter of the stent-graft
Distal diameter of the stent-graft
Number of stent-graft units
T9-T12 intercostal arteries excluded by the stent-graft
Etiology of the aneurysm 
Stent-graft landing zone
Discussion
Dr Randall B. Griepp (New York, NY). I congratulate Dr
Miller and his coworkers on a major contribution to the treat-
ment of patients with thoracic aortic aneurysms. This is the
largest and the best-documented series of endovascular treat-
ment of thoracic aortic aneurysms in the world, and it is also
the best documented in terms of the long-term results. 
However, if the role that stenting will play in the treatment
of thoracic aortic disease is to be determined, a number of
questions need to be asked, and comparisons with contempo-
rary surgical series are appropriate. 
First, an operative mortality of 9% is not bad in this extra-
ordinarily sick group of patients, particularly in light of the
fact that 60% were not deemed to be operative candidates. In
the 40% who were operative candidates, however, only 91%
were alive at 1 year, and this figure is not quite as good as the
results of many contemporary series. Why then should a
patient who is an operative candidate have a stent graft if the
early risk is no lower? 
Stroke occurred in 7% of the patients. This is higher than
one sees in contemporary surgical treatment of this disease. In
all fairness, 8 of these patients had aneurysms that involved
the distal aortic arch or proximal descending thoracic aorta.
Had they been treated surgically, they would have needed
CPB and in all likelihood a period of hypothermic circulatory
arrest to perform a safe and secure proximal anastomosis.
Strokes do occur with a relatively high frequency in patients
so surgically treated; however, even with a high estimate of
25% or so, this would have been only 2 strokes. In the remain-
der of the patients, that is, patients whose aneurysm began 2
cm or so beyond the arch, the risk of stroke is relatively low.
Thus I think 7% is relatively high. Perhaps Dr Miller would
like to state what he thinks can be done to reduce the risk of
stroke in endograft-treated patients in the future. 
Paraplegia occurred in 3%. This, again, is quite low, but it
is not quite comparable with many contemporaneous series
of aneurysms restricted to the descending thoracic aorta. As
Dr Miller has pointed out, this complication occurred when
the graft was deployed in the lower thoracic aorta and a large
number of peridiaphragmatic intercostals were suddenly
occluded. The complication occurred only in those patients
who had undergone previous or were undergoing contempo-
raneous abdominal aortic aneurysm repair. Perhaps in these
patients the stent devices should not be deployed in this area. 
In patients who undergo surgical treatment of thoracic aor-
tic aneurysms, treatment success is pretty much congruent
with survival. It is unusual for patients, at least within the first
few years, to have a form of treatment failure other than
death. A 47% treatment failure by 3.7 years, as seen in this
series, is high compared with that of surgical patients.
Does placement of a stent graft treat the disease? This
question brings up the only significant methodologic argu-
ment I have with Dr Miller’s report. Only 23 of the patients
had CT scans more than 1 year after the stent was placed.
Why was this very important group of patients not followed
up more closely? Nonetheless, among these 23 patients, 11
had a decrease in aneurysm size, but 12, or a slight majority,
either had no change or an increase in aneurysm size. This
failure to regress occurred in the presence or even in the
absence of documented endoleaks. Do many of these patients
have occult endoleaks? Might one anticipate that a certain
proportion of these aneurysms will continue to expand and
ultimately rupture? 
To summarize, then, the stent graft does not work well in
the proximal aorta because it occludes too many peridi-
aphragmatic intercostals and because of the tortuosity that
frequently occurs in this area of the aorta. It does not work
well in chronic aneurysms because of the eccentricity of the
lumen. Its placement is associated with a mortality and mor-
bidity that is not dissimilar from that of surgical treatment. It
may not treat the disease. What then is its role?
Notwithstanding this tirade, I must state that I do believe
that stenting will find a role in the treatment of thoracic aor-
tic aneurysms. It is pioneering studies such as Dr Miller’s that
will help to define this role. 
Dr Miller, can you speculate on the proportion of patients
with descending thoracic aortic aneurysms who ultimately
will be candidates for this endovascular repair? 
This is a truly extraordinary paper in terms of its honest
acknowledgment of the problems that have occurred. It sets a
high standard for all of us who wish to report on innovative
treatments.
Dr Miller. Thank you, Dr. Griepp, for that tirade. It is from
one of my mentors, so I cannot get too angry. 
We have to be honest when we enter these new eras. This
is the only way we are ever going to learn. We were gratified
to see that we actually had learned from our mistakes along
the way within a very short interval of time. For example,
early on we accepted these benign-appearing puffs of con-
trast, endoleaks, as a bad mistake, and we rapidly rectified
that either using another stent graft or coil embolization. 
The survival statistics speak for themselves. I do not know
what the survival data would have been at Mount Sinai, but I
am glad you pointed out that these distal arch aneurysms
would have required profound circulatory arrest. That is not a
walk in the park. 
We admit the stroke rate is too high at 7%. This is readily
explained by the fact that with this primitive device, not just
the guidewire but also the dilator system and the sheath are
wrenching around in the ascending aorta. I was fearful of aor-
tic valve perforations with this chest tube up in the ascending
aorta in these diseased aortas. The newer devices have totally
rectified that. In the Gore Prograf device,* which are now in
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use, the sheath is limited to the abdominal aorta. There is no
dilator system and sheath in the ascending aorta, just the
guidewire. Ideally, that will reduce the incidence of stroke.
We were expecting the paraplegia rate to be higher because
we were deathly afraid that covering all these patent inter-
costals down low was going to wreak the havoc that one
would predict. One might have predicted 10 to 13 cases of
paraplegia whereas we saw only 3. Two of the 3 were in
patients undergoing redo suprarenal abdominal aortic aneur-
ysmectomy, which carries a risk of paraplegia in its own
right. These were not simple cases. The third occurred in a
patient who had had a prior abdominal aortic aneurysm repair
and then had a rupture caused by intramural hematoma. We
had no discrete surgical target and the entire descending tho-
racic aorta was covered. 
Maybe this tells us that your premise from last year’s meet-
ing, that the artery of Adamkiewicz is a myth, is true without
the ischemic preconditioning that your technique involves. I
think we are lucky. Only more numbers and more time will tell. 
The treatment failure rate is high. Most of the failures involved
early endoleaks, a problem that we have rectified. Ideally, the
new devices will be associated with fewer such leaks. 
Does the stent-graft adequately treat the aneurysmal dis-
ease? That is a very important question. The data that Dr
Griepp mentioned are in the manuscript: in half of the
patients we actually documented a decrease of 3 mm or more
in size, and in a quarter there was no change. Those results
may not sound very good, but they are actually much better
than what the vascular surgeons are reporting for stent-graft
repair of abdominal aneurysms. Whether late ruptures may
occur in a very slow, controlled fashion with any of these
methods of treatment remains an open question. We do not
know, but we are encouraged to see in 50% a demonstrable
decrease in size, which is better than any other reported series
in the abdominal aorta. 
The reason for the sad return for CT scans is manifold.
Patients came from all over the United States and abroad, and
we simply could not get them back. That reflects an inade-
quacy on our part and we have to try harder. 
Regarding the proportion of patients with descending tho-
racic aortic aneurysms who ultimately will be candidates for
this endovascular repair, I think we have learned where and
where not to use this procedure. However, we do have new
opportunities. For example, for patients with acute type B
dissection, endovascular repair might be the answer we have
been looking for. Another potential use is for the repair of
acute traumatic tear; none of us likes to do open operations in
those patients. The stent-graft might be the answer.
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